Ratings Silk Road Medical, Inc

Equities

SILK

US82710M1009

Real-time Estimate Cboe BZX Other stock markets 15:02:12 2024-05-16 EDT			5-day change	1st Jan Change
22.64 ^USD	+4.55%		+10.94%	+84.53%

04-30	Transcript : Silk Road Medical, Inc, Q1 2024 Earnings Call, Apr 30, 2024
04-30	Earnings Flash (SILK) SILK ROAD MEDICAL Reports Q1 Revenue $48.5M, vs. Street Est of $44.7M	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
With an enterprise value anticipated at 4.27 times the sales for the current fiscal year, the company turns out to be overvalued.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SILK ROAD MEDICAL, INC	+84.53%	854M	C
ABBOTT LABORATORIES	-4.85%	182B	C+
MEDTRONIC PLC	+3.82%	112B	C
BECTON, DICKINSON AND COMPANY	-2.75%	68.58B	A
DEXCOM, INC.	+5.83%	51.58B	B-
CENCORA, INC.	+7.68%	44.24B	B-
HOYA CORPORATION	+9.45%	43.65B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+25.82%	32.46B	B
TERUMO CORPORATION	+20.94%	25.99B	A-
WEST PHARMACEUTICAL SERVICES, INC.	+1.19%	25.61B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes